OmniAb, Inc. (NASDAQ:OABI) Position Boosted by Barclays PLC

Barclays PLC boosted its holdings in OmniAb, Inc. (NASDAQ:OABI) by 14.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,315 shares of the company’s stock after purchasing an additional 21,100 shares during the quarter. Barclays PLC’s holdings in OmniAb were worth $582,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Choreo LLC bought a new position in shares of OmniAb in the 4th quarter worth about $41,000. Rangeley Capital LLC bought a new position in OmniAb in the fourth quarter worth about $41,000. KLP Kapitalforvaltning AS acquired a new position in OmniAb in the fourth quarter valued at approximately $49,000. SG Americas Securities LLC grew its holdings in shares of OmniAb by 16.5% during the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after purchasing an additional 5,751 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of OmniAb by 24.3% during the 4th quarter. Wells Fargo & Company MN now owns 62,859 shares of the company’s stock worth $223,000 after purchasing an additional 12,278 shares during the period. Institutional investors own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on OABI shares. Royal Bank of Canada lowered their price objective on OmniAb from $7.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research report on Wednesday, March 19th. Finally, Benchmark reduced their price target on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 20th.

Insiders Place Their Bets

In other OmniAb news, CFO Kurt A. Gustafson sold 7,255 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total value of $26,625.85. Following the sale, the chief financial officer now directly owns 206,211 shares in the company, valued at $756,794.37. This trade represents a 3.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Matthew W. Foehr sold 19,382 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $2.00, for a total value of $38,764.00. Following the sale, the chief executive officer now owns 3,796,236 shares in the company, valued at approximately $7,592,472. This represents a 0.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 67,985 shares of company stock valued at $189,773 in the last three months. Insiders own 8.60% of the company’s stock.

OmniAb Trading Up 2.6 %

Shares of OmniAb stock opened at $1.57 on Friday. OmniAb, Inc. has a 52 week low of $1.48 and a 52 week high of $4.96. The company’s 50-day moving average price is $2.28 and its two-hundred day moving average price is $3.22. The stock has a market cap of $191.75 million, a PE ratio of -2.53 and a beta of 0.10.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.17) EPS for the quarter, meeting analysts’ consensus estimates of ($0.17). OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. On average, equities analysts predict that OmniAb, Inc. will post -0.61 EPS for the current fiscal year.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.